The cancer clinical decision tools market consists of sales of cancer decision support tools and related services. Cancer decision tools are designed to support the general practitioner`s assessment of patients with potential cancer symptoms. The tools do not change the clinical judgment but give more information that is used to inform patient management decisions. The risk is measured based on reading coded information from the patient record including demographic data, medical history, and symptoms.
The global cancer clinical decision tools market is expected to decline from $0.38 billion in 2019 to $0.35 billion in 2020 at a compound annual growth rate (CAGR) of -7.41%. The decline is mainly due to the COVID-19 outbreak that has deferred treatment for cancer unless the conditions are serious. The market is then expected to recover and reach $0.47 billion in 2023 at a CAGR of 10.23%.